December 2013 | Oncology Live Urologists in Cancer Care®

February 17, 2014

Much discussion was sparked in the urologic community by an October 2013 article in the journal Urologic Oncology about how the Affordable Care Act (ACA) will affect practicing urologists.

February 14, 2014

A study published in the New England Journal of Medicine sparked controversy and criticism when it claimed that many men received unnecessary radiation therapy for their prostate cancer due to self-referral.

February 13, 2014

An inside look at how the Michigan Institute of Urology is navigating the shifting healthcare and civic landscape.

January 30, 2014

Changing that model will be difficult and disruptive, Becker said, but recognizing the size of the change and developing a plan for managing it will be keys to success in large urology group practices.

January 24, 2014

Organization into large group practices will be a key way for urologists to successfully navigate a healthcare system that continues to be fraught with an enormous amount of change, a keynote speaker said during LUGPA's annual meeting in Chicago in November.

January 22, 2014

Many community-based medical practices are being acquired these days by hospitals that are working to build a steady stream of patients and grow market share.

January 21, 2014

We enjoyed record attendance this year by both physicians and administrators, and despite the pressures of groups being purchased by integrated hospital systems, the organization continues to grow.

January 15, 2014

Poor nutritional status-specifically, a low level of serum albumin-is a predictor of complications following radical cystectomy for patients with bladder cancer

January 14, 2014

As fee-for-service models dwindle under healthcare reform, new reimbursement models based on risk are emerging.

January 09, 2014

Tasquinimod, an experimental immunotherapy and anti-angiogenic agent, prolongs not just progression-free survival (PFS) but also overall survival (OS) in certain men with castration-resistant prostate cancer

December 31, 2013

Patients who undergo androgen deprivation therapy (ADT) to manage advanced prostate cancer will often face the prospect of a potentially dangerous testosterone surge before the downregulation of leuteinizing hormone (LH) secretion occurs and, within about 3 weeks, testosterone drops to castration-like levels.